Navigation Links
Prostate Cancer Vaccine Looks Promising in Early Trial
Date:5/18/2008

Could help men with metastatic, recurring disease, researchers say

SUNDAY, May 18 (HealthDay News) -- A therapeutic vaccine to treat prostate cancer appears safe and may be effective, according to the results of an early trial.

The vaccine could give hope to men with metastatic prostate cancer by activating their immune systems to fight the disease. The vaccine was developed to enable a patient's immune system to produce anti-antigens and attack cancer cells, which can improve quality of life and extend survival.

"The primary objective of the study was to determine whether or not the vaccine was safe or whether it induced any serious adverse events," said lead researcher Dr. David Lubaroff, director of urology research at the University of Iowa. "The vaccine was quite safe."

In addition, the researchers wanted to see if the vaccine produced an immune response to prostate specific antigen (PSA).

"We found that 68 to 70 percent of the patients in the trial demonstrated immune responses to PSA," Lubaroff said. "This was their last resort, and we were encouraged by the fact that we could detect any immune response in these patients."

Results of the phase 1 trial were expected to be presented Sunday at the American Urological Association annual meeting, in Orlando, Fla.

In the trial, Lubaroff's team tested the adenovirus/PSA vaccine in 32 men with metastatic prostate cancer. The men were treated with one of three different doses of the vaccine and followed for 12 months.

In addition to developing immune responses to PSA, 57 percent of the patients survived longer than predicted. Forty-eight percent actually doubled their expected life span. The longest survival was almost six years, the researchers reported.

Based on these results, Lubaroff's group has started a phase II trial, which will determine whether the immune response and survival seen in this trial is really therapeutically meaningful in a larger number of patients.

"If this vaccine proves to induce a strong anti-PSA immune response, and if there is a correlation between this PSA response and an effect on the disease, then we could use this vaccine as another therapy," Lubaroff said.

One expert is skeptical that this vaccine will ever prove to be a viable treatment.

"I think about all you can prove from this kind of study is safety," said Dr. Bruce Roth, a professor of medicine and urology at Vanderbilt University. "But that's a world of difference from saying that there is evidence of efficacy."

Roth doesn't think changes in PSA in this kind of trial are enough to prove the vaccine works.

"I would not take away from this that this is the breakthrough we have been waiting for, for 35 years," Roth said. "It's an OK theory, but we have been disappointed a lot in the past couple of decades with immune therapies that look great but never produce the results we had hoped for."

Another study expected to be presented Sunday showed that a PSA reading taken between the ages of 45 and 50 actually helps predict prostate cancer up to 30 years later. These findings suggest that prostate cancer may start to develop very early and that PSA levels affect the development of prostate cancer.

A third study found that black men who have a family history of prostate cancer could benefit from a PSA reading, which could determine their probability of developing the disease.

Black men who have known risks for prostate cancer and higher levels of PSA are more likely to develop the disease, compared with people in the general population.

However, black men with a family history of prostate cancer are unlikely to develop the disease if their baseline PSA was below what is normal for their age. The effect of family history and PSA level actually overrode other prostate cancer risk factors, the researchers said.

More information

For more on prostate cancer, visit the American Cancer Society.



SOURCES: David Lubaroff, M.D., director, Urology Research, and professor, urology and microbiology, University of Iowa, Iowa City; Bruce Roth, M.D., professor, medicine and urology, Vanderbilt University, Nashville, Tenn.; May 18, 2008, presentation, American Urological Association annual meeting, Orlando


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. First biomarker discovered that predicts prostate cancer outcome
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Red wine compound shown to prevent prostate cancer
7. Barbershop Talks Cut Black Mens Prostate Cancer Risk
8. Generic prostate drug helps find high-risk cancers early
9. Finasteride unlikely to induce high grade prostate cancers
10. Shrinkage of prostate led to overestimation of cancer risk in trial
11. Prostate Cancer Awareness Week to Screen Thousands
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Prostate Cancer Vaccine Looks Promising in Early Trial
(Date:9/19/2017)... ... September 19, 2017 , ... Public outrage over the toxins that exist ... deaf ears, leaving the water industry itself to research, develop and ultimately supply consumers ... curve in the field of natural alkaline water technologies, water filtration ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler ... in the U.S. to incorporate magnesium, a critical property for bone health and ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... Ron Norman, ... candidates today the importance of making a distinct rather than generic impression in the ... had to look through a stack of resumes knows that the first impression they ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... to the Certified Emergency Nurse (CEN®) certification according to a large-scale ... value of certification study, conducted by the Human Resources Research Organization (HumRRO) in ...
(Date:9/18/2017)... , ... September 18, 2017 , ... A September 7 ... in Belfast indicating that aspirin, one of the world’s most common and least expensive ... Los Angeles area dentist Dr. Farzad Feiz of California Dental Group and Calabasas Dental ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent ... as the number one company for hearing aids, ranking it ... fifteen other brands. ... Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, ...
(Date:9/9/2017)... Sept. 8, 2017 Dealmed Medical Supplies, ... of medical equipment, supplies, drugs, vaccines, and specialty medical ... into an agreement to acquire Vantage Medical Supplies, a ... Holtsville, New York . ... new and emerging medical practices, will operate under the ...
Breaking Medicine Technology: